Nov 19, 2025 — Shares of United States Antimony Corporation (NYSE American: UAMY) traded lower on Wednesday while management presented at the 17th Annual Southwest IDEAS Conference and reiterated key growth initiatives tied to U.S. critical‑minerals policy and new commercial contracts.
Key takeaways for today
- Price action: UAMY was down about 4.8% at $6.74 late Wednesday, after opening at $7.32. Intraday range: $7.48 high / $6.735 low; volume ~7.6 million shares as of 23:24 UTC.
- Today’s catalyst: Management used the Southwest IDEAS stage to emphasize the company’s transformation, capacity expansions, and government/commercial contract wins.
- Narrative on the Street: Fresh summaries published today framed UAMY as a leading U.S. antimony supplier benefitting from major government contracts and rapid facility expansion.
What UAMY told investors today
At the Southwest IDEAS Conference (Nov 19–20, Dallas), UAMY’s leadership underscored several points:
- Strategic shift & scale‑up: The Thompson Falls, Montana smelter expansion is slated to lift output roughly fivefold (to about 500 tons/month) “by January,” while the Madero, Mexico facility is targeted to reach ~200 tons/month by year‑end. Investing.com
- Revenue trajectory: Management discussed an expected $40–$43 million revenue range for 2025 and a $125–$150 million outlook for 2026, tied to new contracts and internal supply. (Outlooks are management commentary, not formal guidance.)
- Contracts in focus: UAMY referenced its Defense Logistics Agency (DLA) sole‑source award (up to $245 million over five years) and noted an initial $10 million delivery order currently being filled, alongside a freshly announced multi‑year antimony trioxide deal with a U.S. industrial customer.
Context on today’s event: The Southwest IDEAS investor conference is running Nov 19–20 in the Dallas–Fort Worth area, with dozens of presenting companies.
How the market reacted
Despite the upbeat tone on capacity and contracts, the stock fell ~4.8% to $6.74 late in the session. Trading stayed active, with ~7.6M shares changing hands versus typical averages in the low‑to‑mid teens (millions) this month across financial-data services. As of this afternoon, third‑party trackers pegged UAMY’s equity value around $990 million.
Short, real‑time write‑ups today echoed the conference messaging—government demand, domestic processing capability, and 2026 scaling plans—as the core drivers investors are watching.
Why it matters
- Critical‑minerals positioning: In September, UAMY disclosed a sole‑source, five‑year DLA contract valued at up to $245 million to supply antimony metal for the national defense stockpile—cementing its strategic role as a domestic processor. That backdrop continues to shape investor expectations.
- Commercial demand: On Nov 11, UAMY announced a five‑year antimony trioxide supply agreement (renewable to 10 years) worth up to $106.7 million, supporting non‑defense demand (e.g., flame‑retardant applications). Today’s remarks referenced that deal as part of the company’s near‑term revenue mix.
- Industry currents: Geopolitical moves around antimony and related minerals continue to influence pricing and procurement strategies, a theme management emphasized in today’s discussion.
By the numbers — UAMY today (Nov 19, 2025)
- Last trade:$6.74 (≈ –4.8% day‑over‑day)
- Open / High / Low:$7.32 / $7.48 / $6.735
- Volume:~7.6M shares
- Approx. market cap:~$0.99B
Data as of ~23:24 UTC based on consolidated tape and major financial-data portals.
Recent items investors may reference (not from today)
- DLA stockpile award (Sep 23): up to $245M over five years.
- Antimony trioxide supply agreement (Nov 11): up to $106.7M over five years with renewal option.
- Q3 2025 results call & 8‑K transcript (Nov 12): company furnished the conference‑call transcript to the SEC; replay noted on the IR site.
Bottom line
Today’s news for UAMY centered on management’s Southwest IDEAS presentation, which reinforced the story investors have been trading all fall: domestic antimony capacity expansion + multi‑year government and commercial contracts. Shares slipped on the day despite the constructive long‑term setup, suggesting the market wants to see execution on the ramp (Montana/Mexico), deliveries under the DLA award, and revenue conversion from the new trioxide agreement as 2026 approaches.
This article is for informational purposes only and does not constitute investment advice.
